Immunogenicity of COVID-19 vaccines in patients with cirrhosis: A meta-analysis
Lichen Ouyang1, Gang Lei2, Yeli Gong1
1Department of Immunology, School of Medicine, Jianghan University, Wuhan, China.
Related Experiment Videos
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
12:24A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
06:03Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays
Published on: September 20, 2024
View abstract on PubMed
COVID-19 vaccination shows reduced immune responses in liver cirrhosis patients. Compensated cirrhosis patients had a better response than decompensated ones, highlighting the need for continued monitoring and precautions.
Area of Science:
- Immunology
- Hepatology
- Vaccinology
Background:
- The immunogenicity of COVID-19 vaccines in liver cirrhosis patients is not well understood.
- This meta-analysis aims to evaluate humoral and cellular immune responses to COVID-19 vaccines in cirrhosis patients compared to healthy controls.
Approach:
- A systematic literature search was performed across PubMed, EMBASE, and Web of Science for studies published between January 2020 and August 2023.
- Sixteen studies involving 2127 cirrhosis patients were included in the meta-analysis.
Key Points:
- The pooled seroconversion rate following complete COVID-19 vaccination in cirrhosis patients was 92.4%, with significant heterogeneity.
- Compensated cirrhosis patients exhibited a higher humoral immune response than decompensated patients (RR = 1.069).
- Cirrhosis patients showed a slightly lower seroconversion rate (RR = 0.972) and a significantly diminished cellular immune response (RR = 0.678) compared to healthy controls.
Conclusions:
- COVID-19 vaccination elicits reduced humoral and cellular immune responses in patients with liver cirrhosis.
- Decompensated cirrhosis patients require particular attention and preemptive measures post-vaccination.